According to the lawsuit, defendants made materially false and/or misleading statements and/or failed to disclose that:
- BDC-1001, Bolt’s immune-stimulating antibody conjugate (“ISAC”) designed to target a tumor antigen known as human epidermal growth factor receptor 2 (“HER2”) that is often found in cancers such as breast and gastroesophageal cancer, was less effective than Bolt had represented to investors and was in fact unlikely to meet its pre-defined success criteria;
- accordingly, defendants overstated the clinical and/or commercial prospects of Bolt’s product pipeline, on which Bolt primarily relies to sustain its business model;
- all of the foregoing subjected Bolt to a heightened risk of disruptive leadership transitions and substantial workforce reduction; and
- as a result, Bolt’s public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
